期刊文献+

ERCP术后胰腺炎的相关危险因素分析 被引量:4

下载PDF
导出
摘要 目的探讨经内镜逆行性胰胆管造影(ERCP)术后胰腺炎发生的相关危险因素,为临床实行早期干预提供依据。方法收集882例行ERCP术患者术后3小时血清淀粉酶水平以及其他相关临床资料,跟踪术后胰腺炎发生情况,探讨ERCP术后胰腺炎的相关危险因素。结果 882例中有91例(10.32%)发生胰腺炎,ERCP术后3小时血清淀粉酶>2倍正常值时Youden指数为61.6%,诊断敏感度为84.6%,特异度为77.0%。分析临床资料与患者PEP的相关性,术中插管困难、胆道支架引流术、术前肝功能正常(包括AST、ALT、ALP、GGT、直接以及间接胆红素)、术后24小时淀粉酶>2倍正常值的患者PEP发生率显著升高,差异有统计学意义(P<0.05);进行多因素Logistic回归分析后发现,术前ALP正常、胆道支架引流术以及术后3小时淀粉酶>2倍正常值是ERCP术后导致胰腺炎的独立危险因素。结论 ERCP术后3小时血清淀粉酶可用于PEP的预测,当>2倍正常值时,具有较高的诊断价值,对于术前肝功能正常者或术中行胆道支架引流的患者,应当加强术后观察,以早期采取预防措施来减少PEP发病和降低其严重程度。
出处 《浙江实用医学》 2018年第3期201-204,共4页 Zhejiang Practical Medicine
  • 相关文献

参考文献2

二级参考文献36

  • 1[1]Masci E,Toti G,Mariani A,Curioni S,Lomazzi A,Dinelli M,Minoli G,Crosta C,Comin U,Fertitta A,Prada A,Passoni GR,Testoni PA.Complications of diagnostic and therapeutic ERCP:a prospective multicenter study.Am J Gastroenterol 2001; 96:417-423
  • 2[2]Freeman ML,DiSario JA,Nelson DB,Fennerty MB,Lee JG,Bjorkman DJ,Overby CS,Aas J,Ryan ME,Bochna GS,Shaw MJ,Snady HW,Erickson RV,Moore JP,Roel JP.Risk factors for post-ERCP pancreatitis:a prospective,multicenter study.Gastrointest Endosc 2001; 54:425-434
  • 3[3]Vandervoort J,Soetikno RM,Tham TC,Wong RC,Ferrari AP Jr,Montes H,Roston AD,Slivka A,Lichtenstein DR,Ruymann FW,Van Dam J,Hughes M,Carr-Locke DL.Risk factors for complications after performance of ERCP.Gastrointest Endosc 2002; 56:652-656
  • 4[4]Cotton PB,Lehman G,Vennes J,Geenen JE,Russell RC,Meyers WC,Liguory C,Nickl N.Endoscopic sphincterotomy complications and their management:an attempt at consensus.Gastrointest Endosc 1991; 37:383-393
  • 5[5]Smithline A,Silverman W,Rogers D,Nisi R,Wiersema M,Jamidar P,Hawes R,Lehman G.Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients.Gastrointest Endosc 1993; 39:652-657
  • 6[6]Tarnasky PR,Palesch YY,Cunningham JT,Mauldin PD,Cotton PB,Hawes RH.Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction.Gastroenterology 1998; 115:1518-1524
  • 7[7]Fazel A,Quadri A,Catalano MF,Meyerson SM,Geenen JE.Does a pancreatic duct stent prevent post-ERCP pancreatitis?A prospective randomized study.Gastrointest Endosc 2003; 57:291-294
  • 8[8]Ito K,Fujita N,Noda Y,Kobayashi G,Horaguchi J,Takasawa O,Obana T.The efficacy and safety of prophylactic pancreatic duct stent (Pit-stent) placement in patients at high-risk of post-ERCP pancreatitis.Dig Endosc 2007; in press
  • 9[9]Cavallini G,Tittobello A,Frulloni L,Masci E,Mariana A,Di Francesco V.Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatog raphy.Gabexate in digestive endoscopy-Italian Group.N Engl J Med 1996; 335:919-923
  • 10[10]Masci E,Cavallini G,Mariani A,Frulloni L,Testoni PA,Curioni S,Tittobello A,Uomo G,Costamagna G,Zambelli S,Macarri G,Innocenti P,Dragonetti C.Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.Am J Gastroenterol 2003; 98:2182-2186

共引文献42

同被引文献34

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部